Lethal mutagenesis of the prototypic arenavirus lymphocytic choriomeningitis virus (LCMV)

Carmen M Ruiz-Jarabo1, Calvin Ly, Esteban Domingo

  • 1Centro de Biologia Molecular Severo Ochoa (CSIC, UAM), Universidad Autonoma de Madrid, Cantoblanco, 28049 Madrid, Spain.

Virology
|April 23, 2003
PubMed

Insights

The antiviral 5-fluorouracil (FU) effectively eliminated lymphocytic choriomenigitis virus (LCMV) by inducing lethal mutagenesis. This novel strategy shows promise for treating LCMV infections in vivo.

Area of Science:

  • Virology
  • Molecular Biology
  • Antiviral Research

Background:

  • Lymphocytic choriomenigitis virus (LCMV) is a prototypic arenavirus.
  • Existing antiviral strategies may have limitations.
  • The potential of lethal mutagenesis as an antiviral approach requires further investigation.

Purpose of the Study:

  • To investigate the efficacy of 5-fluorouracil (FU) as a lethal mutagen for eliminating LCMV.
  • To compare FU-mediated viral extinction with ribavirin's antiviral mechanism.
  • To assess the in vivo feasibility of lethal mutagenesis for LCMV infection.

Main Methods:

  • Treatment of cultured cells and mice with FU during LCMV infection.
  • Measurement of viral mutation frequencies, replication, and transcription.
  • Assessment of LCMV minigenome expression.
  • Evaluation of persistent LCMV infection in immunodeficient mice.

Main Results:

  • FU treatment led to efficient LCMV extinction in cell culture without significant cell toxicity.
  • FU significantly increased mutation frequencies in viral genes, with minimal impact on replication and transcription per cycle.
  • Ribavirin inhibited viral RNA synthesis and minigenome expression but did not increase mutation frequencies.
  • FU treatment prevented LCMV persistent infection in vivo in B and T cell-deficient mice.

Conclusions:

  • Lethal mutagenesis using FU is an effective strategy against LCMV, a negative-strand RNA virus.
  • This approach differs mechanistically from ribavirin's antiviral action.
  • In vivo prevention of persistent LCMV infection suggests the potential of lethal mutagenesis as a novel antiviral therapy.